Managers / Q2 2026
PSP Research LLC
CIK 0002106939 · 113 TILLER POINT STREET, LAS VEGAS, NV, 89138 · 617-483-5981
Summary
Psp Research LLC reported $188M in U.S.-listed holdings across 75 positions for Q2 2026.
The portfolio is heavily concentrated: Spdr Series alone accounts for 48.0% of reported value.
Compared with Q1 2026, the fund opened 11 new positions and exited 15.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- ETP · 85.5% · $161M
- Common Stock · 12.1% · $23M
- Other · 1.6% · $3M
- ADR · 0.7% · $1M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2026 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ASCENDIS PHARMA A/S | NEW | +1.5K | 1.5K | +$400,080 | $400,080 |
| LQDALIQUIDIA CORPORATION | NEW | +5.0K | 5.0K | +$398,650 | $398,650 |
| KRYSKRYSTAL BIOTECH INC | NEW | +692 | 692 | +$257,196 | $257,196 |
| AVBPARRIVENT BIOPHARMA INC | NEW | +7.0K | 7.0K | +$244,604 | $244,604 |
| JAZZ PHARMACEUTICALS PLC | NEW | +971 | 971 | +$233,982 | $233,982 |
| RVMDREVOLUTION MEDICINES INC | NEW | +1.2K | 1.2K | +$224,736 | $224,736 |
| RYTMRHYTHM PHARMACEUTICALS INC | NEW | +2.0K | 2.0K | +$222,060 | $222,060 |
| DNLIDENALI THERAPEUTICS INC | NEW | +8.5K | 8.5K | +$217,668 | $217,668 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2026
Filing History
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.